Article

Three Novel Single Nucleotide Polymorphisms (SNPs) of the CYP2B6 Gene in Japanese Individuals

Department of Clinical Pharmaceutics, Tohoku Pharmaceutical University, Sendai, Japan.
Drug Metabolism and Pharmacokinetics (Impact Factor: 2.57). 05/2004; 19(2):155-8. DOI: 10.2133/dmpk.19.155
Source: PubMed

ABSTRACT

We sequenced all exons and exon-intron junctions of the CYP2B6 gene from 200 Japanese individuals. We found three novel single nucleotide polymorphisms (SNPs) (1375A>G, 1427G>A and 1454A>T) causing amino acid substitutions (Met(459)Val, Gly(476)Asp and Gln(485)Leu in exon 9), respectively. The detected SNP was as follows: 1) SNP, 031226Hiratsuka01; GENE NAME, CYP2B6; ACCESSION NUMBER, AC023172; LENGTH, 25 base; 5'-CAGAACTTCTCCA/GTGGCCAGCCCCG-3'. 2) SNP, 031226Hiratsuka02; GENE NAME, CYP2B6; ACCESSION NUMBER, AC023172; LENGTH, 25 base; 5'-CCCAGGAGTGTGG/ATGTGGGCAAAAT-3'. 3) SNP, 031226Hiratsuka03; GENE NAME, CYP2B6; ACCESSION NUMBER, AC023172; LENGTH, 25 base; 5'-CCCCAACATACCA/TGATCCGCTTCCT-3'.

Download full-text

Full-text

Available from: Masahiro Hiratsuka
  • Source
    • "Some of these variations are rare, but many are common, with allele frequencies between 10% and almost 50%, depending on the population (Klein et al. 2005; Solus et al. 2004). Ethnic or racial inter-individual CYP2B6 polymorphism in various populations has been reported in Caucasians (Lang et al. 2001), Japanese (Hiratsuka et al. 2002and Hiratsuka et al. 2004), African-American-Hispanic (Lamba et al. 2003; Hesse et al. 2004), Korean (Cho et al. 2004), Mongolian (Davalkham et al. 2009), Spain (Novoa et al. 2005), and South Indians (Ramachandran et al. 2009), but not in North Indian population, and, hence, CYP2B6 was selected in this study. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Identification of poor and rapid metabolizers for the category of drugs metabolized by cytochrome P450 2B6 (CYP2B6) is important for understanding the differences in clinical responses of drugs metabolized by this enzyme. This study reports the prevalence of poor and rapid metabolizers in North Indian population residing in the National Capital Territory. The prevalence of poor and rapid metabolizers was determined in the target population for the category of drugs metabolized by CYP2B6 by measuring plasma bupropion, a drug metabolized by CYP2B6, and its metabolite. Bupropion (75 mg) was administered to 107 volunteers, and the drug (bupropion) and its metabolite (hydroxybupropion) were determined simultaneously by LCMS/MS in the plasma. CYP2B6 activity was measured as hydroxybupropion/bupropion ratio, and volunteers were categorized as rapid or poor metabolizers on the basis of cutoff value of log (hydroxybupropion/bupropion). Significant differences were observed between the mean metabolite/drug ratio of rapid metabolizers (Mean = 0.59) and poor metabolizers (Mean = 0.26) with p<0.0001. Results indicate that 20.56% individuals in the target population were poor metabolizers for the category of drugs metabolized by CYP2B6. Cutoff value defined in this study can be used as a tool for evaluating the status of CYP2B6 using bupropion as a probe drug. The baseline information would be clinically useful before administering the drugs metabolized by this isoform.
    Full-text · Article · Oct 2012 · SpringerPlus
  • Source
    • "For genotyping of CYP2B6 983TrC (rs28399499), new primers and probes were designed as follows: forward primer, 5 -GCCTGAAATGCCTCTTTAAA- ATGAGATTC-3 ; reverse primer, 5 -GCGATGTGGGCCAAT- CAC-3 ; VIC probe for 983T, 5 -CTGTTCAATCTCCC-3 ; and FAM probe for 983C, 5 -CTGTTCAGTCTCCC-3 . The obtained genotyping results of CYP2B6 983TrC for 110 patients were confirmed by direct sequencing of exons 7 and 8 with use of primers published elsewhere [9]. Plasma EFV concentration. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Efavirenz (EFV) is metabolized primarily by cytochrome P450 2B6 (CYP2B6), and high plasma concentrations of the drug are associated with a G-->T polymorphism at position 516 (516G-->T) of CYP2B6 and frequent central nervous system (CNS)-related side effects. Here, we tested the feasibility of genotype-based dose reduction of EFV. CYP2B6 genotypes were determined in 456 human immunodeficiency virus type 1 (HIV-1)-infected patients who were receiving EFV treatment or were scheduled to receive EFV-containing treatment. EFV dose was reduced in CYP2B6 516G-->T carriers who had high plasma EFV concentrations while receiving the standard dosage (600 mg). EFV-naive homozygous CYP2B6 516G-->T carriers were treated with low-dose EFV. In both groups, the dose was further reduced when plasma EFV concentration remained high. CYP2B6 516G-->T was identified in the *6 allele (found in 17.9% of our subjects) and a novel allele, *26 (found in 1.3% of our patients). All EFV-treated CYP2B6 *6/*6 and *6/*26 carriers had extremely high plasma EFV concentrations (>6000 ng/mL) while receiving the standard dosage. EFV dose was reduced to 400 mg for 11 patients and to 200 mg for 7 patients with persistently suppressed HIV-1 loads. EFV-containing treatment was initiated at 400 mg in 4 CYP2B6 *6/*6 carriers and one *6/*26 carrier. Two of them still had a high plasma EFV concentration while receiving that dose, and the dose was further reduced to 200 mg, with successful HIV-1 suppression. CNS-related symptoms improved with dose reduction in 10 of the 14 patients, although some had not been aware of the symptoms at initial dosage. Genotype-based EFV dose reduction is feasible in CYP2B6 *6/*6 and *6/*26 carriers, which can reduce EFV-associated CNS symptoms.
    Preview · Article · Nov 2007 · Clinical Infectious Diseases
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The zebrafish is an in vivo model system originally used to study development of vertebrates. Over the last years it has gained a more important role in studies focusing on diseases such as cancer and thrombosis. Platelets play an important role in thrombosis and therefore drugs inhibiting platelet enzymes and receptors are developed to prevent thrombosis. The most effective drugs inhibit the COX enzymes (aspirin) or the platelet activating receptor P2Y-12 (clopidogrel among others). Lack of clarity exists about the P2Y12 receptor. In T2DM patients, there is speculation that there is less inhibition by 16 antagonists. Also the current insight in P2Y12 signaling is limited to suppression of production of cAMP (a platelet inhibitor) and activation of protein kinase B/Rap1b (which stimulate aggregation). Aims of the thesis: (1) To evaluate the position of the zebrafish as a model system in research on platelet function and thrombus; (2) Discuss the main problems the currently most used anti-platelet drugs (aspirin and clopidogrel) possess; (3) To study the inhibition of the P2Y-12 receptor in diabetes patients and to demonstrate which secondary signalling molecules are activated by P2Y-12
    Preview · Article ·
Show more